ClinicalTrials.gg

Program

CT-P55

Its studies are mostly in Psoriasis, led by Celltrion.

Furthest: phase 3, since Oct 7, 20242 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Celltrion21 open or runningphase 3since Oct 7, 2024Oct 7, 2024none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 7, 2024First study: phase 3 study in Plaque PsoriasisFirst studyNCT06630559 · 153 enrolled · Poland
  2. Jun 22, 2025Phase 1 study in Healthy Male SubjectsNCT07054970 · 172 enrolled · Japan

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07054970Healthy Male Subjects · Japan1CompletedAug 29, 2024172
NCT06630559Plaque Psoriasis · Poland3Active, not recruitingFeb 18, 2026153

How it is read

Names in the registry

  • “CT-P55”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.